CN114588247B - Active peptide probiotic composition and application thereof in preparation of food or medicine with effects of promoting intestinal peristalsis and/or relieving constipation - Google Patents
Active peptide probiotic composition and application thereof in preparation of food or medicine with effects of promoting intestinal peristalsis and/or relieving constipation Download PDFInfo
- Publication number
- CN114588247B CN114588247B CN202210266497.6A CN202210266497A CN114588247B CN 114588247 B CN114588247 B CN 114588247B CN 202210266497 A CN202210266497 A CN 202210266497A CN 114588247 B CN114588247 B CN 114588247B
- Authority
- CN
- China
- Prior art keywords
- peptide
- molecular weight
- bovine liver
- soybean
- probiotic composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 171
- 239000006041 probiotic Substances 0.000 title claims abstract description 88
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 88
- 230000000529 probiotic effect Effects 0.000 title claims abstract description 50
- 239000000203 mixture Substances 0.000 title claims abstract description 49
- 206010010774 Constipation Diseases 0.000 title claims abstract description 45
- 230000000968 intestinal effect Effects 0.000 title claims abstract description 36
- 230000008855 peristalsis Effects 0.000 title claims abstract description 32
- 230000000694 effects Effects 0.000 title claims abstract description 30
- 230000001737 promoting effect Effects 0.000 title claims abstract description 28
- 239000003814 drug Substances 0.000 title claims abstract description 22
- 235000013305 food Nutrition 0.000 title claims abstract description 8
- 238000002360 preparation method Methods 0.000 title claims description 9
- 241000283690 Bos taurus Species 0.000 claims abstract description 63
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 63
- 210000004185 liver Anatomy 0.000 claims abstract description 62
- 244000068988 Glycine max Species 0.000 claims abstract description 56
- 241001608472 Bifidobacterium longum Species 0.000 claims abstract description 15
- 229940009291 bifidobacterium longum Drugs 0.000 claims abstract description 15
- 240000001046 Lactobacillus acidophilus Species 0.000 claims abstract description 14
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims abstract description 14
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims abstract description 14
- 244000199866 Lactobacillus casei Species 0.000 claims abstract description 12
- 235000013958 Lactobacillus casei Nutrition 0.000 claims abstract description 12
- 229940017800 lactobacillus casei Drugs 0.000 claims abstract description 12
- 241000186016 Bifidobacterium bifidum Species 0.000 claims abstract description 8
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims abstract description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 12
- 238000000502 dialysis Methods 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 235000011837 pasties Nutrition 0.000 claims description 4
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 claims 1
- 235000021336 beef liver Nutrition 0.000 claims 1
- 229940004120 bifidobacterium infantis Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 12
- 238000011160 research Methods 0.000 abstract description 4
- 239000004480 active ingredient Substances 0.000 abstract description 2
- KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 description 14
- 206010016100 Faeces discoloured Diseases 0.000 description 10
- 241000700159 Rattus Species 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- 230000013872 defecation Effects 0.000 description 5
- 230000030136 gastric emptying Effects 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 210000000813 small intestine Anatomy 0.000 description 5
- 241000186000 Bifidobacterium Species 0.000 description 4
- 235000013339 cereals Nutrition 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000002550 fecal effect Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 239000008141 laxative Substances 0.000 description 2
- 229940125722 laxative agent Drugs 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 206010002153 Anal fissure Diseases 0.000 description 1
- 208000016583 Anus disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000009531 Fissure in Ano Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010036774 Proctitis Diseases 0.000 description 1
- 208000015815 Rectal disease Diseases 0.000 description 1
- 240000004980 Rheum officinale Species 0.000 description 1
- 235000008081 Rheum officinale Nutrition 0.000 description 1
- 206010066792 Stomach mass Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000007160 gastrointestinal dysfunction Effects 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000008944 intestinal immunity Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000008143 stimulant laxative Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/185—Vegetable proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/011—Hydrolysed proteins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Botany (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to the technical field of biomedicine, and particularly discloses an active peptide probiotic composition and application thereof in preparing foods or medicines with the effects of promoting intestinal peristalsis and/or relieving constipation. The active peptide probiotic composition comprises bovine liver peptide, soybean peptide and probiotics; the weight ratio of the bovine liver peptide to the soybean peptide to the probiotics is 1-3:1-3:0.02-0.1; the bovine liver peptide is bovine liver peptide with molecular weight less than 1 kD; the soybean peptide is soybean peptide with molecular weight less than 1 kD. The probiotics comprise bifidobacterium bifidum, bifidobacterium longum subspecies infantis, lactobacillus acidophilus and lactobacillus casei. Research shows that the active peptide probiotic composition has very excellent effects of promoting intestinal peristalsis and relieving constipation; therefore, the active ingredient can be used for preparing foods or medicines with the effects of promoting intestinal peristalsis and/or relieving constipation.
Description
Technical Field
The invention relates to the technical field of biomedicine, in particular to an active peptide probiotic composition and application thereof in preparing foods or medicines with the effects of promoting intestinal peristalsis and/or relieving constipation.
Background
Constipation refers to a decrease in the frequency of defecation (less than 2-3 times of defecation per week) compared with normal people, accompanied by a laborious defecation, and a small amount of feces and dryness. Constipation is not only a disease, but also may be the manifestation of certain diseases, and long-term constipation can induce anorectal diseases such as proctitis, anal fissure and the like; also can increase abdominal pressure to induce cardiovascular and cerebrovascular diseases due to constipation; secondly, the hard fecal mass presses the intestinal cavity to narrow the intestinal cavity and structures around the pelvic cavity to obstruct the expansion of the colon, so that the rectum or the colon is pressed to form fecal ulcers; in addition, the accumulated and metabolized products are retained in the intestinal tract, and a large amount of harmful gases can be generated under the action of bacteria to influence the brain functions and the like. The medicine for treating constipation in clinic mainly comprises chemical medicines (stimulant laxatives, lubricating laxatives and hypertonic laxatives) and Chinese herbal compound preparations. The chemical medicine has strong irritation to intestinal tracts, can cause aggravation of illness state after long-term use, is easy to cause gastrointestinal dysfunction, and is easy to relapse after stopping medicine.
Probiotics are a class of microorganisms beneficial to a host that colonize the skin or intestinal tract of the human body and are capable of altering the composition of the host's flora at a location. Research shows that compared with the common medicines for treating constipation such as rheum officinale and diarrhea agents in clinic, the probiotics for treating constipation can promote intestinal peristalsis and relieve constipation. Compared with the medicine for treating constipation, the probiotic has no adverse reaction after long-term use, and has remarkable advantages. A large number of researches show that the bioactive peptide separated from plants or animals has the functions of intestinal immunity, maintaining intestinal host-microorganism steady state, regulating intestinal-brain axis and the like as a bioactive molecule.
However, there are few reports of promoting intestinal peristalsis and relieving constipation after combining active peptides and probiotics; it is not known to those skilled in the art whether the active peptide and the probiotic are combined to promote intestinal peristalsis and relieve constipation better than the active peptide or probiotic alone. Therefore, the development of a composition with better effect of promoting intestinal peristalsis or relieving constipation than the single use of active peptide or probiotics has important application value.
Disclosure of Invention
In view of the above, the invention firstly provides an active peptide probiotic composition, and further researches show that the active peptide probiotic composition has excellent effects of promoting intestinal peristalsis and relieving constipation.
The detailed technical scheme of the invention is as follows:
an active peptide probiotic composition comprising bovine liver peptide, soy peptide and a probiotic.
The prior art does not report that the bovine liver peptide and the soybean peptide have the functions of promoting intestinal peristalsis and relieving constipation; neither is any active peptide having the effect of promoting intestinal peristalsis and relieving constipation. In a great number of experimental processes, the invention surprisingly finds that the bovine liver peptide and the soybean peptide have the effects of promoting intestinal peristalsis and relieving constipation. Therefore, the composition obtained by combining the bovine liver peptide, the soybean peptide and the probiotics has the effects of promoting intestinal peristalsis and relieving constipation.
Preferably, the weight ratio of the bovine liver peptide to the soybean peptide to the probiotics is 1-3:1-3:0.02-0.1.
Further preferably, the weight ratio of the bovine liver peptide to the soybean peptide to the probiotics is 1-2:1-2:0.02-0.05;
preferably, the weight ratio of the bovine liver peptide to the soybean peptide to the probiotics is 1:1:0.02.
Preferably, the bovine liver peptide is a bovine liver peptide with a molecular weight of less than 1 kD.
Preferably, the bovine liver peptide with the molecular weight less than 1kD is prepared by the following method:
dissolving bovine liver peptide in 2-5 times of water to obtain bovine liver peptide solution, dialyzing with dialysis bag with aperture of 1kD, collecting dialysate, and lyophilizing to obtain bovine liver peptide with molecular weight less than 1 kD.
Preferably, the soybean peptide is a soybean peptide with a molecular weight of less than 1 kD.
Preferably, the soybean peptide with the molecular weight less than 1kD is prepared by the following method:
dissolving soybean peptide in 2-5 times of water to obtain soybean peptide solution, dialyzing with dialysis bag with aperture of 1kD, collecting dialysate, and lyophilizing to obtain soybean peptide with molecular weight less than 1 kD.
In further studies, the inventors have found that not all molecular weight active peptides in combination with probiotics are able to enhance each other's effect in promoting intestinal peristalsis and alleviating constipation; the inventors have surprisingly found during a number of studies that a composition formed by combining a bovine liver peptide having a molecular weight of less than 1kD and a soy peptide having a molecular weight of less than 1kD with a probiotic can significantly improve the effect of each other in promoting intestinal peristalsis and alleviating constipation; the resulting composition, which promotes intestinal peristalsis and relieves constipation, is far better than either bovine liver peptide alone having a molecular weight of less than 1kD or soybean peptide alone having a molecular weight of less than 1kD or probiotic alone.
However, compositions of other molecular weight bovine and soy peptides in combination with probiotics have not been shown to have an effect on each other in promoting intestinal peristalsis and alleviating constipation; the resulting composition does not significantly improve the effect of individual bovine liver peptides having a molecular weight of less than 1kD or individual soy peptides having a molecular weight of less than 1kD or individual probiotics in promoting intestinal peristalsis and alleviating constipation.
Preferably, the probiotics comprise bifidobacterium bifidum, bifidobacterium longum subspecies infantis, lactobacillus acidophilus and lactobacillus casei.
Preferably, the weight ratio of the bifidobacterium longum to the bifidobacterium longum subspecies infantis to the lactobacillus acidophilus to the lactobacillus casei is 1-3:1-3;
most preferably, the weight ratio of bifidobacteria, bifidobacterium longum subspecies infantis, lactobacillus acidophilus, lactobacillus casei is 1:1:1:1.
The preparation method of the active peptide probiotic composition comprises the steps of preparing the bovine liver peptide and the soybean peptide into pasty liquid with the solid content of 5-10% by using water, freeze-drying and preparing into powder; and then uniformly mixing the active peptide probiotic composition with probiotics to obtain the active peptide probiotic composition.
The application of the active peptide probiotic composition in preparing foods or medicines with the effects of promoting intestinal peristalsis and/or relieving constipation.
The beneficial effects are that: the invention discovers that the bovine liver peptide and the soybean peptide have the functions of promoting the intestinal peristalsis and relieving constipation for the first time, thus providing a brand-new active peptide probiotic composition with the functions of promoting the intestinal peristalsis and relieving constipation; the inventors have surprisingly found in further studies that a composition of bovine liver peptide having a molecular weight of less than 1kD and soy peptide having a molecular weight of less than 1kD in combination with a probiotic has a very significant effect in promoting intestinal peristalsis and alleviating constipation, better than the use of bovine liver peptide, soy peptide or probiotic alone. Because the active peptide probiotic composition has very excellent effect of promoting intestinal peristalsis and relieving constipation; therefore, the active ingredient can be used for preparing foods or medicines with the effects of promoting intestinal peristalsis and/or relieving constipation.
Detailed Description
The technical scheme of the present invention will be clearly and completely described in the following examples. It will be apparent that the described embodiments are only some, but not all, embodiments of the invention. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
The bifidobacterium bifidum, bifidobacterium longum subspecies infantis, lactobacillus acidophilus and lactobacillus casei used in the examples below are all powdered products which can be purchased by a person skilled in the art by conventional means.
EXAMPLE 1 preparation of active peptide probiotic compositions
Mixing bovine liver peptide with molecular weight less than 1kD and soybean peptide with molecular weight less than 1kD with water to obtain pasty liquid with solid content of 8%, lyophilizing, and making into powder; then evenly mixing the active peptide probiotic composition with probiotics to obtain the active peptide probiotic composition;
bovine liver peptide with molecular weight less than 1kD, soybean peptide with molecular weight less than 1kD and probiotics are in a weight ratio of 1:1:0.02;
the probiotics comprise bifidobacteria, bifidobacterium longum subspecies infantis and lactobacillus acidophilus and lactobacillus casei in a weight ratio of 1:1:1:1;
the bovine liver peptide with the molecular weight less than 1kD is prepared by the following method: dissolving bovine liver peptide in 4 times of water to obtain bovine liver peptide solution, dialyzing with dialysis bag with aperture of 1kD, collecting dialysate, and lyophilizing to obtain bovine liver peptide with molecular weight less than 1 kD;
the soybean peptide with the molecular weight less than 1kD is prepared by the following method: dissolving soybean peptide in 4 times of water to obtain soybean peptide solution, dialyzing with dialysis bag with aperture of 1kD, collecting dialysate, and lyophilizing to obtain soybean peptide with molecular weight less than 1 kD.
EXAMPLE 2 preparation of active peptide probiotic compositions
Mixing bovine liver peptide with molecular weight less than 1kD and soybean peptide with molecular weight less than 1kD with water to obtain pasty liquid with solid content of 5%, lyophilizing, and making into powder; then evenly mixing the active peptide probiotic composition with probiotics to obtain the active peptide probiotic composition;
bovine liver peptide with molecular weight less than 1kD, soybean peptide with molecular weight less than 1kD and probiotics are in a weight ratio of 3:1:0.04;
the probiotics comprise bifidobacteria, bifidobacterium longum subspecies infantis and lactobacillus acidophilus in a weight ratio of 3:1:3:1;
the bovine liver peptide with the molecular weight less than 1kD is prepared by the following method: dissolving bovine liver peptide in 2 times of water to obtain bovine liver peptide solution, dialyzing with dialysis bag with aperture of 1kD, collecting dialysate, and lyophilizing to obtain bovine liver peptide with molecular weight less than 1 kD;
the soybean peptide with the molecular weight less than 1kD is prepared by the following method: dissolving soybean peptide in 2 times of water to obtain soybean peptide solution, dialyzing with dialysis bag with aperture of 1kD, collecting dialysate, and lyophilizing to obtain soybean peptide with molecular weight less than 1 kD.
EXAMPLE 3 preparation of active peptide probiotic compositions
Mixing bovine liver peptide with molecular weight less than 1kD and soybean peptide with molecular weight less than 1kD with water to obtain slurry liquid with solid content of 10%, lyophilizing, and making into powder; then evenly mixing the active peptide probiotic composition with probiotics to obtain the active peptide probiotic composition;
bovine liver peptide with molecular weight less than 1kD, soybean peptide with molecular weight less than 1kD and probiotics are in a weight ratio of 1:3:0.01;
the probiotics comprise bifidobacteria, bifidobacterium longum subspecies infantis and lactobacillus acidophilus in a weight ratio of 1:3:3:3;
the bovine liver peptide with the molecular weight less than 1kD is prepared by the following method: dissolving bovine liver peptide in 5 times of water to obtain bovine liver peptide solution, dialyzing with dialysis bag with aperture of 1kD, collecting dialysate, and lyophilizing to obtain bovine liver peptide with molecular weight less than 1 kD;
the soybean peptide with the molecular weight less than 1kD is prepared by the following method: dissolving soybean peptide in 5 times of water to obtain soybean peptide solution, dialyzing with dialysis bag with aperture of 1kD, collecting dialysate, and lyophilizing to obtain soybean peptide with molecular weight less than 1 kD.
Example 4 experiment of activated carbon probiotic composition to promote intestinal peristalsis and relieve Constipation
Rats were randomly divided into a control group, a model group, a phenolphthalein (0.05 g/kg) group, a bovine liver peptide (molecular weight less than 1kD,0.3 g/kg) group, a soybean peptide (molecular weight less than 1kD,0.3 g/kg) group and probiotics (composed of bifidobacterium bifidum, bifidobacterium longum subspecies infantis, lactobacillus acidophilus and lactobacillus casei in a weight ratio of 1:1:1:1, 0.3 g/kg) group, which were prepared as described in example 1, and an active peptide probiotic composition (0.3 g/kg) prepared as described in example 1; each group of 10. On days 1-4, the control group is fed with conventional feed, the model group and each administration group are fed with rice and water is forbidden to establish a constipation model. On days 5-8, each group was fed with a conventional feed, and each administration group was filled with the corresponding drug (10 mL/kg), and the control group and the model group were filled with the same amount of physiological saline 1 time/d. On day 8, the rats of each group were perfused with a carbon powder suspension (10 mL/kg) and then with a corresponding drug, the time of black stool of the first granule of each rat was recorded, the total number of stools and the number of black stools within 6 hours, and the water content of the feces was measured. After cervical vertebra removal and sacrifice of each group of rats, taking the whole stomach tissue, and weighing the whole stomach mass and the net mass; the mesentery was separated, the intestinal tube was cut, the total length of the small intestine and the carbon powder advancing length were measured, and the gastric emptying rate and the small intestine advancing rate were calculated. Wherein, the calculation formulas of the gastric emptying rate and the small intestine propulsion rate are as follows: gastric emptying rate = 1- (stomach full mass-stomach net mass)/0.6; small intestine push rate = ink push length/small intestine total length.
TABLE 1 influence of active peptide probiotic compositions on constipation rat stool parameters
As can be seen from the experimental data in Table 1, compared with the control group, the first grain of the rats in the model group has obviously increased black stool time (p < 0.01), the defecation number and the black stool number of 6 hours are obviously reduced (p < 0.01), and the fecal moisture content is obviously reduced (p < 0.01), which indicates that the preparation of the desiccation model is successful.
From the experimental data in Table 1, it can be seen that the bovine liver peptide with the molecular weight less than 1kD and the soybean peptide with the molecular weight less than 1kD prepared in the embodiment 1 of the invention have obviously improved the black stool time, the stool number and the black stool number of the first grains of the rats and the water content of the excrement; this shows that the bovine liver peptide with the molecular weight less than 1kD prepared by the invention has obvious constipation relieving effect.
From the experimental data in Table 1, it can be seen that the probiotics consisting of bifidobacterium bifidum, bifidobacterium longum subspecies infantis, lactobacillus acidophilus and lactobacillus casei in the weight ratio of 1:1:1:1 are superior to the positive drug phenolphthalein in terms of indexes such as the first grain black stool time, the 6h stool number, the black stool number, the water content of excrement and the like; the probiotics consisting of the bifidobacterium bifidum, the bifidobacterium longum subspecies infantis, the lactobacillus acidophilus and the lactobacillus casei in the weight ratio of 1:1:1:1 have better constipation relieving effect than the positive medicine phenolphthalein and very excellent constipation relieving effect.
From the experimental data in table 1, it can be seen that the active peptide probiotic composition group prepared in example 1 is far better than the single bovine liver peptide with molecular weight less than 1kD, the single soybean peptide with molecular weight less than 1kD and the probiotics composed in example 1 in terms of the indexes such as the first grain black stool time, the 6h defecation number, the black stool number and the water content of the excrement, and the like, and is also far better than the positive drug phenolphthalein; this illustrates: the composition formed by combining the bovine liver peptide with the molecular weight less than 1kD and the soybean peptide with the molecular weight less than 1kD and probiotics can obviously improve the effect of each other in relieving constipation; the active peptide probiotic composition has far better constipation relieving effect than single bovine liver peptide with molecular weight less than 1kD or single soybean peptide with molecular weight less than 1kD or single probiotic, and far better positive medicine phenolphthalein, and has very obvious constipation relieving effect.
TABLE 2 Effect of active peptide and probiotic compositions on gastrointestinal motility in constipation rats
As can be seen from the experimental data in Table 2, the bovine liver peptide with the molecular weight less than 1kD, the soybean peptide with the molecular weight less than 1kD and the ratio of the probiotics group to the model group prepared in the embodiment 1 of the invention can obviously improve the gastric emptying rate and the carbon end propulsion rate; this shows that the bovine liver peptide with a molecular weight of less than 1kD, the soybean peptide with a molecular weight of less than 1kD and the probiotics prepared in example 1 have the effect of promoting intestinal peristalsis.
As can be seen from the experimental data in table 2, the active peptide probiotic composition group prepared in example 1 has a much higher rate of increase in gastric emptying rate and carbon end pushing rate than that of bovine liver peptide with molecular weight less than 1kD, soybean peptide with molecular weight less than 1kD and probiotics composed in example 1, and is also higher than that of the positive drug phenolphthalein; this illustrates: the composition formed by combining the bovine liver peptide with the molecular weight less than 1kD and the soybean peptide with the molecular weight less than 1kD with probiotics can obviously improve the effect of each other in promoting intestinal peristalsis; the active peptide probiotic composition has far better effect on promoting intestinal peristalsis than single bovine liver peptide with molecular weight less than 1kD or single soybean peptide with molecular weight less than 1kD or single probiotic, is also better than positive medicine phenolphthalein, and has very obvious effect on promoting intestinal peristalsis.
Finally, it is noted that the above-mentioned preferred embodiments are only intended to illustrate rather than limit the invention, and that, although the invention has been described in detail by means of the above-mentioned preferred embodiments, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention as defined by the appended claims.
Claims (5)
1. An active peptide probiotic composition, comprising bovine liver peptide, soybean peptide and probiotics;
the weight ratio of the bovine liver peptide to the soybean peptide to the probiotics is 1-2:1-2:0.02-0.05;
the bovine liver peptide is bovine liver peptide with molecular weight smaller than 1 kD; the molecular weight of the beef liver is less than 1kD
The peptide is prepared by the following method: dissolving bovine liver peptide in 2-5 times of water to obtain bovine liver peptide solution, dialyzing with dialysis bag with aperture of 1kD, collecting dialysate, and lyophilizing to obtain bovine liver peptide with molecular weight less than 1 kD;
the soybean peptide is soybean peptide with molecular weight smaller than 1 kD; the soybean peptide with the molecular weight smaller than 1kD is prepared by the following method: dissolving soybean peptide in 2-5 times of water to obtain soybean peptide solution, dialyzing with dialysis bag with aperture of 1kD, collecting dialysate, and lyophilizing to obtain soybean peptide with molecular weight less than 1 kD;
the probiotics comprise bifidobacterium bifidum, bifidobacterium longum subspecies infantis, lactobacillus acidophilus and lactobacillus casei; the weight ratio of the bifidobacterium longum to the bifidobacterium infantis subspecies longum to the lactobacillus acidophilus to the lactobacillus casei is 1-3:1-3.
2. The active peptide probiotic composition according to claim 1, wherein the weight ratio of bovine liver peptide, soy peptide and probiotic is 1:1:0.02.
3. The active peptide probiotic composition according to claim 1, characterized in that the weight ratio of bifidobacterium bifidum, bifidobacterium longum subspecies infantis, lactobacillus acidophilus, lactobacillus casei is 1:1:1.
4. A method for preparing an active peptide probiotic composition according to any one of claims 1 to 3, characterized in that bovine liver peptide and soybean peptide are prepared into a pasty liquid with a solid content of 5 to 10% with water, and lyophilized to prepare a powder; and then uniformly mixing the active peptide probiotic composition with probiotics to obtain the active peptide probiotic composition.
5. Use of the active peptide probiotic composition according to any one of claims 1 to 3 in the preparation of a food or medicament having an effect of promoting intestinal peristalsis and/or alleviating constipation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210266497.6A CN114588247B (en) | 2022-03-18 | 2022-03-18 | Active peptide probiotic composition and application thereof in preparation of food or medicine with effects of promoting intestinal peristalsis and/or relieving constipation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210266497.6A CN114588247B (en) | 2022-03-18 | 2022-03-18 | Active peptide probiotic composition and application thereof in preparation of food or medicine with effects of promoting intestinal peristalsis and/or relieving constipation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114588247A CN114588247A (en) | 2022-06-07 |
| CN114588247B true CN114588247B (en) | 2024-01-26 |
Family
ID=81811304
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210266497.6A Active CN114588247B (en) | 2022-03-18 | 2022-03-18 | Active peptide probiotic composition and application thereof in preparation of food or medicine with effects of promoting intestinal peristalsis and/or relieving constipation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114588247B (en) |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004269407A (en) * | 2003-03-07 | 2004-09-30 | Aureo Co Ltd | Constipation ameliorant and food and beverage containing the same |
| JP2007124973A (en) * | 2005-11-07 | 2007-05-24 | Taiyo Corp | Method for producing soybean peptide |
| KR20120108821A (en) * | 2011-03-25 | 2012-10-05 | 허교 | Composition for improvement of egg-laying ratio and cholesterol content egg comprising oy-bean fermented peptide with probiotics and fulvic acid as active component |
| JP2016029065A (en) * | 2015-09-18 | 2016-03-03 | 糧三 齋藤 | Composition for improving intestinal environment and intestinal tract barrier |
| CN107836721A (en) * | 2017-12-11 | 2018-03-27 | 青岛四季康健生物科技有限公司 | A kind of composition with intestines and stomach healthcare function and preparation method thereof |
| CN111616374A (en) * | 2020-07-23 | 2020-09-04 | 西咸新区优恩生物科技股份有限公司 | Nutrient for improving and regulating physical functions of athletes and astronauts |
| CN113151056A (en) * | 2021-03-18 | 2021-07-23 | 仙乐健康科技股份有限公司 | Probiotic composition, preparation method and application thereof |
| CN114225004A (en) * | 2022-01-27 | 2022-03-25 | 上海朗泰凯尔生物技术有限公司 | Intestinal motility promoting and constipation resisting probiotic composition and preparation method thereof |
-
2022
- 2022-03-18 CN CN202210266497.6A patent/CN114588247B/en active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004269407A (en) * | 2003-03-07 | 2004-09-30 | Aureo Co Ltd | Constipation ameliorant and food and beverage containing the same |
| JP2007124973A (en) * | 2005-11-07 | 2007-05-24 | Taiyo Corp | Method for producing soybean peptide |
| KR20120108821A (en) * | 2011-03-25 | 2012-10-05 | 허교 | Composition for improvement of egg-laying ratio and cholesterol content egg comprising oy-bean fermented peptide with probiotics and fulvic acid as active component |
| JP2016029065A (en) * | 2015-09-18 | 2016-03-03 | 糧三 齋藤 | Composition for improving intestinal environment and intestinal tract barrier |
| CN107836721A (en) * | 2017-12-11 | 2018-03-27 | 青岛四季康健生物科技有限公司 | A kind of composition with intestines and stomach healthcare function and preparation method thereof |
| CN111616374A (en) * | 2020-07-23 | 2020-09-04 | 西咸新区优恩生物科技股份有限公司 | Nutrient for improving and regulating physical functions of athletes and astronauts |
| CN113151056A (en) * | 2021-03-18 | 2021-07-23 | 仙乐健康科技股份有限公司 | Probiotic composition, preparation method and application thereof |
| CN114225004A (en) * | 2022-01-27 | 2022-03-25 | 上海朗泰凯尔生物技术有限公司 | Intestinal motility promoting and constipation resisting probiotic composition and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| Impact of food-derived bioactive peptides on gut function and health;Xiaoyu Bao等;Food Research International;第147卷;第110485（1-19）页 * |
| 新生牛肝活性肽对小鼠的免疫增强作用;傅颖等;中国生物制品杂志;第21卷(第1期);第47-50页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114588247A (en) | 2022-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113855712B (en) | Composition capable of promoting defecation and application thereof | |
| CN104740138A (en) | Composition containing aloe, probiotics and prebiotics and application of composition | |
| CN103764154A (en) | Pharmaceutical compositions containing pediococcus and methods for reducing the symptoms of gastroenterological syndromes | |
| CN113151056A (en) | Probiotic composition, preparation method and application thereof | |
| CN114225004A (en) | Intestinal motility promoting and constipation resisting probiotic composition and preparation method thereof | |
| JPH0656680A (en) | Nutritional and/or pharmaceutical composi- tion containing freeze-dried lactic acid bacterium and preparation and use thereof | |
| CN115074298A (en) | Probiotic composition with effects of resisting claustrophobia, protecting stomach and promoting digestion and eliminating stagnation and application thereof | |
| CN114681493B (en) | Application of bifidobacterium animalis subspecies lactis | |
| CN114343183A (en) | Polysaccharide and probiotic composition for regulating and controlling intestinal anti-constipation activity | |
| CN104161263B (en) | The full nutritional formulas of child | |
| CN115216423B (en) | Bifidobacterium animalis SF and application thereof in medicines and foods | |
| CN114831286A (en) | Composition with constipation relieving function and preparation method thereof | |
| KR20140026326A (en) | Compositions and methods for augmenting kidney function | |
| CN114698848B (en) | Active polysaccharide and probiotic composition and application thereof in preparation of health-care food or medicine with constipation relieving effect | |
| CN114588247B (en) | Active peptide probiotic composition and application thereof in preparation of food or medicine with effects of promoting intestinal peristalsis and/or relieving constipation | |
| CN116622587B (en) | Probiotic prepared by synthetic biological method, composition and application thereof | |
| CN111296847A (en) | Cereal probiotic preparation for regulating intestinal microecology and preparation method and application thereof | |
| CN104146267B (en) | The full nutritional formulas of lupus erythematosus | |
| CN1622816A (en) | Composition and method for augmenting kidney function | |
| CN110721202B (en) | Fecal bacteria capsule and preparation method thereof | |
| CN114145460A (en) | Lactic acid bacteria, composition containing same and application | |
| CN106974940B (en) | Application of probiotics of scleritis in treating and preventing obesity and related diseases | |
| WO2019205506A1 (en) | Egg-shaped bacteroides for relieving endotoxin infection and application thereof | |
| CN117568244B (en) | Probiotic agent for improving digestion and nutrient absorption capacity and application thereof | |
| CN104757549B (en) | One kind relaxes bowel composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |